Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Yuwa Ando[1], Tomokazu Kawaoka[1], Masanari Kosaka[1], Yuki Shirane[1], Yusuke Johira[1], Ryoichi Miura[1], Serami Murakami[1], Shigeki Yano[1], Kei Amioka[1], Kensuke Naruto[1], Yumi Kosaka[1], Shinsuke Uchikawa[1], Kenichiro Kodama[1], Hatsue Fujino[1], Takashi Nakahara[1], Atushi Ono[1], Eisuke Murakami[1], Masami Yamauchi[1,2], Wataru Okamoto[1,2], Shoichi Takahashi[1], Michio Imamura[1], Hiroshi Aikata[1]

1. Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

2. Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.

Running head: Risk factors for proteinuria in patients receiving atezolizumab + bevacizumab

Corresponding author: Hiroshi Aikata

Department of Gastroenterology and Metabolism, Graduate School of

Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi,

Minamiku, Hiroshima 734-8551, Japan. Telephone: +81-82-257-5192, Fax: +81-

82-257-5194,

E-mail: aikata@hiroshima-u.ac.jp

Number of Tables: 3

Number of Figures: 6

Word count: 2943 words

Abstract

Introduction

Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo+Bev) and can cause interruption in the use of Bev. However, the risk factors for proteinuria in patients with hepatocellular carcinoma (HCC) who are receiving Atezo+Bev have not yet been investigated. The aim of this study was to identify the risk factors for early onset of proteinuria in Atezo+Bev for patients with unresectable HCC.

Methods

Sixty-four patients with Child-Pugh scores of 5–7, an eastern cooperative oncology group performance status of 0 or 1, and low level of proteinuria (1+ or less on a dipstick test and urine protein to creatinine ratio (UPCR) less than 2.0 g/g Cr) at the initiation of therapy were analyzed. The level of proteinuria was evaluated based on the Common Terminology Criteria for Adverse Events version 5.0. We adopted the UPCR for the quantitative test instead of a 24-h urine collection. The incidence of proteinuria and changes in liver function were retrospectively investigated.

Results

The cumulative incidence of proteinuria over a 24-week period was 34.4%. Multivariate analysis showed that a low estimated glomerular filtration rate (hazard ratio (HR), 3.807; 95% confidence interval (CI), 1.579–9.180; $p = 0.003$), treatment for hypertension (HR, 6.224; 95% CI, 1.614–24.010; $p = 0.008$) and high systolic blood pressure (SBP) (HR, 2.649; 95% CI, 1.133–6.194; $p = 0.025$) were risk factors for proteinuria. Serum albumin levels and albumin-bilirubin scores in patients with proteinuria worsened. In addition, a mean SBP $\geq$ 135 mm Hg during treatment was the only risk factor for the development of severe proteinuria (UPCR > 2 g/g Cr).

Conclusion

Our study found that controlling blood pressure is extremely important for the management of proteinuria in patients with HCC who are receiving Atezo+Bev.

1. Introduction

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide [1]. HCC occurs commonly in patients with chronic hepatitis or liver cirrhosis secondary to either hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, excessive alcohol intake, nonalcoholic steatohepatitis, or diabetes [2]. While the development of antiviral therapy has resulted in a relative decrease in the occurrence of HCC due to HBV and HCV infections, an increase in patients with non-B– non-C–related HCC in patients with nonalcoholic steatohepatitis and metabolic syndrome has become a problem [3, 4].

Atezolizumab plus bevacizumab (Atezo+Bev) combination therapy was approved in 2020 as the first combined immunotherapy for HCC. Atezolizumab is a humanized monoclonal antibody to programmed cell death ligand 1 (PD-L1). It blocks the binding of PD-L1 to PD-1 and thereby boosts anticancer immunity [5]. Bevacizumab targets vascular endothelial growth factor (VEGF), which stimulates angiogenesis and the growth of tumors [6, 7].

The IMbrave150 trial found that Atezo+Bev resulted in longer maintenance of the quality of life and better survival benefits than sorafenib [8]. The results of that trial suggest that Atezo+Bev should be a useful systemic therapy for HCC,

and should be used as a first-line treatment [9, 10]. However, proteinuria is known to be a major adverse event (AE) of Atezo+Bev for patients with HCC. Indeed, the incidence of proteinuria in the Imbrave150 trial was 20.1% [8].

In real-world practice, proteinuria associated with Atezo+Bev has occured frequently, and has been a major cause of interruption in the use of Bev [11, 12]. Negative consequences regarding antitumor efficacy when Bev treatment was interrupted early during the treatment of patients with HCC have also been reported [12]. Thus, the management of proteinuria in patients with HCC is important for maximizing the therapeutic effects of Atezo+Bev.

Patients treated with bevacizumab are monitored regularly for proteinuria by a dipstick test of a urine sample. The current standard for the management of patients treated with bevacizumab requires a 24-h urine protein test for a dipstick test result of $\geq$ 2+ proteinuria, with the further recommendation that bevacizumab treatment should be interrupted for a protein level of $\geq$ 2 g/24 h.

The 24-h urine protein test requires an overnight collection of urine by the patient, which is burdensome. The results also are affected by patient compliance. However, a urine protein to creatinine ratio (UPCR, g/g Cr) < 2.0 g/g in a single-void urine sample is known to correlate significantly with 24-h

proteinuria [13, 14]. Hence, in clinical practice, we often adopt the UPCR instead of the quantification of protein in a 24-h urine collection as an assessment of the degree of proteinuria.

Predictive factors for proteinuria in patients receiving Bev for several cancers have already been reported [15, 16]. However, the risk factors for proteinuria associated with anti-VEGF treatment for patients with HCC have not yet been investigated. Therefore, this retrospective study focused on identifying the risk factors for early onset of proteinuria in patients with unresectable HCC being treated by Atezo+Bev.

2. MATERIALS AND METHODS

Patients

This retrospective cohort study included 87 patients treated with Atezo+Bev for unresectable HCC at our hospital from September 2020 to October 2021. We examined their records and collected their clinical data obtained during the treatment period. Patients positive for anti-HCV antibodies were considered to have HCC associated with HCV infection, while those positive for HBV surface antigen were considered to have HCC associated with HBV infection. Other patients were considered to have non-B, non-C hepatitis associated with HCC. 23

patients who had poor liver function or high-level proteinuria at baseline were excluded. Finally, a total of 64 patients with Child-Pugh scores ranging from 5 to 7, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and low-level proteinuria (1+ or less on the dipstick test and a UPCR < 2.0 g/g Cr) at the initiation of therapy were analyzed.

Treatment regimen

Patients received 1200 mg of Atezo plus 15 mg per kg of body weight of Bev intravenously every 3 weeks. Interruptions to treatment and dose modifications were permitted for adverse drug reactions and the patient's general condition. Patients continued the therapy until death or one of the following criteria was met for the cessation of therapy: progressive disease following treatments, adverse events that required termination of treatment, increase in ECOG PS to 4, worsening liver function, or withdrawal of consent. Bev treatment was interrupted for a UPCR of ≥ 2.0 g/g Cr, and was restarted when the UPCR decreased to < 2.0 g/g Cr.

Assessment of treatment outcome

The evaluation used by imaging was performed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline [17] with computed

tomography and magnetic resonance imaging. Overall survival was defined as the time from initiation until death from any cause. Progression-free survival was defined as the period from initiation until the time of radiological progression by RECIST or any cause of death.

Blood pressure

Systolic and diastolic blood pressures (SBPs and DBPs) were recorded between 9 am and 10 am when a study patient visited our hospital. The presence of hypertension in a study patient was assessed by a recorded prescription for an antihypertensive agent. The mean SBP/DBP during treatment was calculated as follows: mean SBP/DBP = the sum of SBPs/DBPs measured before every treatment divided by the number of treatments.

Proteinuria

Proteinuria was defined according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. A urine dipstick test and UPCR were performed at baseline and at every regular visit. UPCR was used as the quantitative test instead of a 24-h urine collection. Severe proteinuria was defined as a UPCR > 2g/g Cr.

Liver function

The ALBI score was used for liver function. The ALBI score was determined

from laboratory test results for albumin and total bilirubin, where available. The

following equation was used: ALBI score = (log$_{10}$ bilirubin (μmoL/L) × 0.66) +

(albumin (g/L) × −0.085) [18]. Modified ALBI (mALBI) grades were assigned

according to the ALBI scores as follows: ALBI score ≤ −2.60 was grade 1, −2.60

< ALBI score ≤ −2.27 was grade 2a, −2.27 < ALBI score ≤ −1.39 was grade 2b,

and ALBI score > −1.39 was grade 3 [19].

Statistical analysis

Statistical analyses were performed using EZR ver. 1.53 software [20].

Normality for continuous variables was examined using the Kolmogorov-

Smirnov test. The paired T-test was used to compare between normally

distributed continuous variables, and the Mann-Whitney test was used to

compare non-normally distributed continuous variables. The Kaplan-Meier

method was used to determine cumulative incidence. The log-rank test and Cox

proportional hazards regression were used for univariate and multivariate

analysis, respectively. Correlation analysis was performed using Spearman's rank

correlation coefficient. Continuous variables were expressed as means or

medians, and categorical variables were expressed as absolute and relative

frequencies. Optimal cutoff thresholds were determined by receiver operating characteristic curve analysis. A p value < 0.05 was considered to be statistically significant.

3. RESULTS

Patient background characteristics

Table 1 shows the baseline clinical characteristics of the 64 study patients (48 men, 16 women) at the initiation of Atezo+Bev treatment. The median patient age was 70 (47–90) years. Thirty-seven (57.8%), 20 (31.3%), and 7 (10.9%) patients had Child Pugh scores 5, 6, or 7, respectively. There were 41 patients (64.1%) who were being treated for hypertension. The median baseline UPCR of the study patients was 0.16 g/g Cr; 13 (20.3%) patients were positive for proteinuria (1+ on the dipstick test). Atezo+Bev was administered to 35 patients as first-line therapy and to 29 patients as second-line or subsequent therapy. The median number of treatment cycles was 6, and the median observation period was 8.1 months.

Treatment outcome

Based on the RECIST 1.1 guidelines, the proportions of patients at the time of their best response were as follows: complete response 1.6%, partial response

23.4%, stable disease 53.1%, and progressive disease 21.9%. The objective

response rate was 25.0%. The median survival time was not reached, and the

median progression-free survival was 7.8 months.

Cumulative incidence of proteinuria

Figure 1a shows the cumulative incidence of proteinuria among all patients

analyzed. The cumulative incidences of proteinuria at 6, 12, and 24 weeks were

9.4%, 25.0%, and 34.4% respectively. Univariate analysis showed a relationship

between proteinuria and the following variables: estimated glomerular filtration

rate (eGFR), treatment for hypertension, SBP, and UPCR at baseline.

Multivariate analysis showed that an eGFR $\leq$ 63 mL/min/1.73 m² (hazard ratio

(HR)), 3.807; 95% confidence interval (CI)), 1.579–9.180; $p = 0.003$), treatment

for hypertension (HR, 6.224; 95% CI, 1.614–24.010; $p = 0.008$) and SBP $\geq$130

mm Hg (HR, 2.649; 95% CI, 1.133–6.194; $p = 0.025$) were significant and

independent risk factors of proteinuria (Table 2, Fig. 1b-1d).

The patients were divided into 4 groups based on whether or not at baseline

they were taking antihypertensive drugs and had an SBP $\geq$ 130 mm Hg at

baseline: patients with SBP $\geq$ 130 mm Hg and taking antihypertensive drugs had

the highest risk of proteinuria, and patients with SBP < 130 mm Hg and not taking antihypertensive drugs had the lowest risk of proteinuria (Fig. 2).

Changes in ALBI scores, serum Alb levels, and serum total Bil levels

Figure 3 shows relative changes in ALBI scores, serum albumin levels, and serum total bilirubin levels in 50 patients who underwent 5 treatment cycles. There were 22 patients with and 28 patients without proteinuria. In the patients with proteinuria, ALBI scores worsened significantly at cycle 2 (-2.459 ± 0.425 vs -2.286 ± 0.438, $p = 0.009$), cycle 4 (-2.299 ± 0.499, $p = 0.009$), and cycle 5 (-2.271 ± 0.491, $p = 0.017$), compared to those at baseline. Similarly, the serum albumin levels in patients with proteinuria also had significantly deteriorated from baseline to cycle 2 (3.759 ± 0.457 vs 3.527 ± 0.478, respectively; $p = 0.004$), to cycle 4 (3.554 ± 0.555, respectively; $p = 0.008$) and to cycle 5 (3.543 ± 0.532, respectively; $p = 0.021$). On the other hand, patients without proteinuria did not show these changes over the 5 cycles. The changes in serum total bilirubin levels of patients with or without proteinuria were not significant.

Cumulative incidence of severe proteinuria among patients with proteinuria

Among 22 patients with proteinuria during treatment, 14 developed severe proteinuria (UPCR > 2g/g Cr). The patients with severe proteinuria had a

significantly higher mean SBP during treatment compared to the patients with mild proteinuria (UPCR $\leq$ 2 g/g Cr) (Fig. 4). Univariate analysis showed a relationship between severe proteinuria and, UPCR at baseline and a mean SBP during treatment. Multivariate analysis showed that a mean SBP during treatment $\geq$135 mm Hg was the only significant and independent risk factor of severe proteinuria (HR, 6.909; 95% CI, 1.436–33.230; $p = 0.016$) (Table 3, Fig. 5).

Figure 6 shows the correlation between mean systolic and diastolic blood pressure during treatment and maximum UPCR recorded during treatment in 22 patients with proteinuria. Significant positive correlations of mean SBP and maximum UPCR were detected (r = 0.578, $p = 0.005$)

4. Discussion

The aim of our study was to predict the early onset of proteinuria in patients with unresectable HCC treated with Atezo+Bev using factors before treatment. The cumulative incidence of proteinuria at 6, 12, and 24 weeks were 9.4%, 25.0%, and 34.4% respectively. Our study found significant relationships between proteinuria and the following variables: SBP, treatment for hypertension, and eGFR at baseline. We also found that serum albumin levels and ALBI scores in patients with proteinuria were deteriorated. On the other

hand, pretreatment factors could not predict the development of severe

proteinuria, and the mean SBP during treatment was the only risk factor for

development of severe proteinuria requiring interruption Bev. To our best

knowledge, this is the first report to examine the risk factors for early onset of

proteinuria in HCC patients treated with Atezo+Bev.

Since its approval in 2020, Atezo+Bev has been widely used for patients with

unresectable HCC in clinical practice, and there are many published reports on

the efficacy and safety of this combination [11, 12]. A phase 1b study showed

that the addition of Bev strengthened the antitumor effect of Atezo. Patients

treated with Atezo+Bev had a longer progression-free survival than those treated

with Atezo monotherapy [21]. In a real-world practice, Hatanaka et al. reported

on the negative consequences regarding antitumor efficacy when Bev treatment

was interrupted early during the treatment of patients with HCC [12]. They

showed that the early interruption of Bev treatment was a significant adverse

factor associated with PFS ($p = 0.021$) and OS ($p = 0.008$), and that proteinuria

was more frequently found in patients whose Bev treatment was interrupted than

in those whose treatment was not interrupted (35.9% vs 18.0%, *p=0.005*). In

other words, to maximize the antitumor effects of Atezo+Bev in patients with

unresectable HCC, it is essential to prevent the interruption of Bev treatment by

providing the timely and careful management of AEs such as proteinuria.

In our study, of the 22 patients with proteinuria, 14 (63.6%) showed severe

proteinuria (UPCR > 2 g/g Cr) requiring the interruption of Bev. These patients

had higher mean SBP during treatment than patients without severe proteinuria.

Based on previous research, hypertension and proteinuria may be related [22]. It

is hypothesized that proteinuria may also result from increased intraglomerular

pressure secondary to arterial hypertension. We also showed a positive

correlation between mean SBP and maximum UPCR recorded during treatment.

Therefore, the adequate control of BP during treatment may prevent the

interruption of Bev treatment due to proteinuria.

Inhibitors of VEGF or the signaling of VEGF receptors (VEGFRs) induce

hypertension resulting from the increased production of nitric oxide and the

rarefaction of microvascular endothelial cells [23]. Proteinuria due to anti-

VEGF/VEGFR agents is caused not only by disorders associated with elevated

systemic and glomerular blood pressure, but also by disruption of podocyte

integrity [24-26]. In addition, thrombotic microangiopathy with reduced VEGF

within the kidney was reported to result in profound glomerular injury [27].

Predictive factors for proteinuria in treatments using Bev for various cancers have already been reported [28-30]. Previous articles reported that drug dose, elevated BP, and certain types of antihypertensive agents were risk factors for proteinuria. However, proteinuria that occurs during anti-VEGF treatment for patients with HCC has not yet been fully investigated. To date, the following 6 systemic therapies have been approved for the treatment of patients with unresectable HCC: Atezo+Bev, sorafenib, and lenvatinib as first-line treatments; and regorafenib, cabozantinib, and ramucirumab as second-line treatments [31-35]. All of these drugs have anti-VEGF/anti-VEGFR activity, and therefore can cause hypertension and proteinuria.

In our study, patients with proteinuria had significantly worse serum albumin levels and ALBI scores. Although previous reports showed early deterioration of ALBI grade during Atezo+Bev treatment, the exact reason is unknown. However, in many reports, there was a temporary decline in liver function at cycle 2, and improvement was observed at cycle 3 and 4 [11, 36]. In this study, the ALBI grade and serum albumin levels in patients without onset of proteinuria worsened at cycle 2 but remained stable thereafter, consistent with previous reports. On the other hand, in patients with proteinuria, the ALBI grade, which

had temporarily improved, worsened again in the 4th cycle. This change is newly

observed, and the effect of proteinuria must be considered. However, if a

decrease in ALBI grade was observed in patients with proteinuria due to the loss

of albumin from the urine, this fact is unlikely to reflect a direct deterioration in

hepatic reserve function.

Patients treated with Atezo+Bev for HCC are considered to have a higher risk

for proteinuria than patients treated with other MTAs previously. First, the

relative increase in patients with non-B, non-C hepatitis associated with HCC is a

major problem. Nagaoki et al. reported that patients with non-B, non-C hepatitis

associated with HCC have a significantly higher rate of hypertension, type 2

diabetes, and dyslipidemia than patients with HCC associated with infections due

to hepatis B and C [4]. In our study, there were 28 (43.8%) patients with non-B,

non-C hepatitis associated with HCC, which was a higher proportion than in the

IMbrave 150 trial (100/336, 29.8%). Second, Atezo+Bev is often used as second-

line or subsequent therapy in clinical practice. Patients with a previous history of

other MTAs may already have hypertension and proteinuria. This study included

29 (45.3%) patients with a previous history of MTA treatment. In fact, the

incidence of proteinuria in our study was higher than in the IMbrave 150 trial

(34.4% vs. 20.1%) [8]. Our study might have consisted of many patients who already had risk factors for proteinuria. Third, the dose of Bev used to treat HCC is high, at 15 mg per kg of body weight. It has already been reported that there was a significant dose-dependent increase in the risk of proteinuria and hypertension in patients treated with Bev [28]. Thus, proteinuria must be very carefully managed in Atezo+Bev for patients with unresectable HCC.

This study has limitations. It was a retrospective study of a very small number of patients with a very short observation period. In addition, the associations between proteinuria and types of antihypertensive agents and the changes in antitumor effects caused by the withdrawal of Bev were not demonstrated. Actual measures for managing proteinuria are also issues in the future. Therefore, a more definitive conclusion requires a longer observation period and a larger number of study patients. Nevertheless, we have shown that SBP, treatment for hypertension, and eGFR were significant predictors of the early development of proteinuria in HCC patients treated with Atezo+Bev.

In conclusion, the blood pressure control is an extremely important factor in the management of proteinuria in patients with HCC treated with Atezo+Bev.

We believe that this information will be very useful for the management of patients receiving Atezo+Bev in real-world practice.

Statement of Ethics

This study was approved by the Ethics Review Committee of Hiroshima University (project identification code number E-2300) on December 15, 2020. This was a retrospective analysis of records stored in a database. Written informed consent was obtained from participants to participate in the study. It received official approval that was based on the Guidelines for Clinical Research issued by the Ministry of Health and Welfare in Japan. All procedures complied with the Declaration of Helsinki.

Conflicts of Interest Statement

Michio Imamura has received honoraria from Bristol-Myers Squibb and research funding from Bristol-Meyers Squibb.

Funding Sources

The authors did not receive any funding for this study.

Author Contributions

Yuwa Ando: conceptualization, formal analysis, original draft; Tomokazu Kawaoka: conceptualization, review, editing; Masanari Kosaka, Yuki Shirane, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yumi Kosaka: data curation; Shinsuke Uchikawa, Kenichiro Kodama, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura: treated the patients; Hiroshi Aikata: review, editing. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

References

1   Forner A, Reig M, Bruix, J. Hepatocellular carcinoma. *Lancet* 2018; 391:1301-14.

2   Singal A.G, El-Serag H.B. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. *Clin. Gastroenterol. Hepatol*. 2015; 13:2140-51.

3   Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A
nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-
2015 update. *J Gastroenterol.* 2019; 54:367-76.

4   Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, et al.
Increasing incidence of non-HBV- and non-HCV-related hepatocellular
carcinoma: single-institution 20-year study. *BMC Gastroenterol.* 2021; 21(1):
306.

5   Herbst R.S, Soria J-C, Kowanetz M, Fine G.D, Hamid O, Gordon M.S, et al.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in
cancer patients. *Nature.* 2014; 515:563-567.

6   Ferrara N, Hillan K.J, Novotny W. Bevacizumab (Avastin), a humanized
anti-VEGF monoclonal antibody for cancer therapy. *Biochem Biophys Res
Commun.* 2005; 333:328-335.

7   Finn R.S, Bentley G, Britten C.D, Amado R, Busuttil R.W. Targeting
vascular endothelial growth factor with the monoclonal antibody bevacizumab
inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse
model. *Liver Int.* 2009; 29:284-290.

8   Finn R.S, Qin S, Ikeda M, Galle P.R, Ducreux M, Kim T.Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl. J. Med.* 2020, 382, 1894-1905.

9   European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol*. 2018; 69:182-236.

10   Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: Mechanism, pharmacokinetics and future treatment strategies. *Future Oncol.* 2021.

11   Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, et al. Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresecable hepatocellular carcinoma in real-world practice. *Cancers (Basel).* 2021 Aug 5;13(16):3958.

12   Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. *Hepatol Res*. 2022 Jan 25. doi: 10.1111/hepr.13748.

13   Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. *N Engl J Med.* 1983; 309(25):1543-1546.

14   Yang CY, Chen FA, Chen CF, Liu WS, Shih CJ, Ou SM, et al. Diagnostic accuracy of urine protein/creatinine ratio is influenced by urine concentration. *PLoS One.* 2015;10: e0137460.

15   Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. *J Am Soc Nephrol*. 2010; 21:1381-1389.

16   Hirai T, Shuji Y, Takiya M, Hanada K, Itoh T. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis. *Cancer Chemother Pharmacol*. 2019; 84(1):195-202.

17   L.H.; Seymour, L.; Litière, S.; Ford, R.; Gwyther, S.; Mandrekar, S.; Shankar, L.; Bogaerts, J.; Chen, A.; Dancey, J.; et al. RECIST 1.1— Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur. J. Cancer 2016; 62:138-145.

18   Johnson P.J, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H.L, et al. Assessment of liver function in patients with hepatocellular

carcinoma: A new evidence-based approach-the ALBI grade. *J. Clin. Oncol.* 2015; 33:550-558.

19   Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, et al. Validation of modified ALBI grade for more detailed assessing hepatic function of hepatocellular carcinoma - multicenter analysis. *Liver Cancer*. 2019; 8: 121-129.

20   Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplantation* 2013; 48:452-8.

21   Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicenter, phase 1b study. *Lancet Oncol.* 2020; 21:808-20.

22   Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J Clin Oncol.* 2005; 23:792–99

23   David CS, Lauren A, K Bridget B. Angiogenic growth factors and hypertension. Angiogenesis. 2004; 7(3):193-201.

24   Laura C, Maurizio G, Wanda L, Camillo P. Renal toxicity of anticancer

agents targeting vascular endothelial growth factor (VEGF) and its receptors

(VEGFRs). *J Nephrol.* 2017; 30(2):171-180.

25   Pierre R. Proteinuria; is it all in the foot? *J Clin Invest.* 2007; 117(8):2079-

82.

26   Rexford SA. Linking adiponectin to proteinuria. *J Clin Invest.* 2008;

118(5):1619-22.

27   Eremina V, Jefferson JA, Kowalewska J et al (2008) VEGF inhibition and

renal thrombotic microangiopathy. *N Engl J Med.* 2008; 358:1129-1136.

28   Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension

with bevacizumab, an antibody against vascular endothelial growth factor:

systematic review and meta-analysis. *Am J Kidney Dis*. 2007; 49(2):186-93.

29   Nihei S, Sato J, Harada T, Kuyama S, Suzuki T, Waga N, et al.

Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients

receiving bevacizumab. *Cancer Chemother Pharmacol*. 2018; 81(6):1051-1059.

30   Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E, et

al. Predictive factors for the development of proteinuria in cancer patients treated

with bevacizumab, ramucirumab, and aflibercept: a single-institution

retrospective analysis. *Sci Rep.* 2020; 10(1): 2011.

31　Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and

safety of sorafenib in patients in the Asia-Pacific region with advanced

hepatocellular carcinoma: a phase III randomized, double-blind, placebo-

controlled trial. *Lancet Oncol.* 2009; 10:25-34.

32　Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib

versus sorafenib in first-line treatment of patients with unresectable

hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. *Lancet.*

2018; 391:1163-73.

33　Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al.

Regorafenib for patients with hepatocellular carcinoma who progressed on

sorafenib treatment (RESORCE): a randomised double-blind, placebo-controlled,

phase 3 trail. Lancet. 2017; 389:56-66.

34　Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo

BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular

carcinoma. *N Eng L Med.* 2018; 379:54-63.

35   Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma

and increased alpha-fetoprotein concentration (REACH-2): a randomised,

double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019; 20:282-96.

36   Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al.

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular

carcinoma: Early clinical experience. *Cancer Rep (Hoboken).* 2022; 5(2).

Figure Legends

Fig. 1. Cumulative incidence of proteinuria

a. All patients.

b. Systolic blood pressure.

c. Estimated glomerular filtration rate.

d. Treatment for hypertension.

Fig. 2. Cumulative incidence of proteinuria, with patients divided into 4 groups according to systolic blood pressure and treatment with antihypertensive (aHT) agents

Fig. 3. Changes in albumin-bilirubin (ALBI) scores, serum albumin levels, and serum total-bilirubin levels

Test: the paired T-test.

a. ALBI scores.

b. Serum albumin levels.

c. Serum total-bilirubin levels.

Fig. 4. Comparison of blood pressures during treatment between patients with severe proteinuria and patients with mild proteinuria.

Severe proteinuria: a UPCR >2g/g Cr. Test: the Mann-Whitney test.

a. Systolic blood pressure

b. Diastolic blood pressure

Fig. 5. Cumulative incidence of severe proteinuria according to mean systolic blood pressure (SBP).

Severe proteinuria: a UPCR >2g/g Cr

Fig. 6. Association of mean systolic and mean diastolic blood pressure with maximum UPCR recorded during treatment

a. Mean systolic blood pressure: r=0.578, *p=0.005*.

b. Mean diastolic blood pressure: r=0.28, *p=0.207*.

Table 1.

Clinical background at initiation of atezolizumab plus bevacizumab combination therapy.

Age (yr), range	70 (47-90)	HbA1c (%), range	5.8 (4.1-8.8)
Sex (males/females), n	48/16	Proteinuria at baseline ($-$ or $\pm/+1$), n	51/13
Etiology (HBV/HCV/nonB nonC), n	10/26/28	UPCR (g/gCre), range	0.16 (0.01-1.25)
Child-Pugh score (5/6/7), n	37/20/7	ECOG performance status (0/1), n	60/4
Modified ALBI grade (1/2a/2b), n	24/17/23	BCLC stage (A/B/C), n	1/31/32
Serum BUN level (mg/dL), range	16.0 (8.1-57.7)	Macrovascular invasion (with/without), n	17/47
Serum creatinine lever (mg/dL), range	0.83 (0.45-2.06)	Extrahepatic metastasis (with/without), n	23/41
eGFR (mL/min/1.73m^2), range	67 (25-137)	Serum AFP level (ng/mL), range	61.4 (1.4-35780)
Treatment for hypertension (with/without), n	41/23	Serum DCP level (mAU/mL), range	357.5 (15-201200)
Ca blocker (with/without), n	38/3	History of MTAs (with/without), n	29/35
ACE-I or ARB (with/without), n	19/22	Number of treatment cycles	6 (2-17)
α or β blocker (with/without), n	8/33	Observation period (months), range	8.1 (2.8-14.0)

HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI, albumin-bilirubin; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin II receptor blocker; UPCR, urinary protein-to-creatinine ratio; ECOG, eastern cooperative oncology group; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin; MTA, molecular targeted agent.

Table 2.

Univariate and multivariate analyses of risk factors for proteinuria during treatment.

Variable	Univariate	Multivariate		
	P value*	HR	95% CI	P value**
Sex (male vs female)	0.336			
Etiology (viral vs non-viral)	0.615			
ECOG performance status (1 vs 0)	0.779			
Child-Pugh score (6 or 7 vs 5)	0.071			
Modified ALBI grade (2b vs 1 or 2a)	0.664			
eGFR ($\leq$63 vs >63) (mL/min/1.73m²)	<0.001	3.807	1.579-9.180	0.003
Treatment for hypertension (with vs without)	0.002	6.224	1.614-24.010	0.008
Treatment of diabetes (with vs without)	0.781			
Systolic BP at baseline ($\geq$130 vs <130) (mmHg)	0.002	2.649	1.133-6.194	0.025
Diastolic BP at base line ($\geq$69 vs <69) (mmHg)	0.091			
Macrovascular invasion (with vs without)	0.468			
Extrahepatic metastasis (with vs without)	0.856			
History of MTAs (with vs without)	0.718			
UPCR at baseline ($\geq$0.35 vs <0.35) (g/gCre)	<0.001			

*Log-rank test, ** Cox proportional hazard regression.

HR, hazard ratio; CI, confidence interval; ECOG, eastern cooperative oncology group; ALBI, albumin-bilirubin; eGFR, estimated glomerular filtration rate; BP, blood pressure; MTA, molecular targeted agent; UPCR, urinary protein-to-creatinine ratio.

Table 3.

Univariate and multivariate analyses of risk factors for severe proteinuria during treatment.

Variable	Univariate	Multivariate		
	*P value**	HR	95% CI	*P value***
Sex (male vs female)	0.180			
Etiology (viral vs non-viral)	0.282			
ECOG performance status (1 vs 0)	0.607			
Child-Pugh score (6 or 7 vs 5)	0.460			
Modified ALBI grade (2b vs 1 or 2a)	0.474			
eGFR ($\leq$63 vs >63) (mL/min/1.73m²)	0.114			
Treatment for hypertension (with vs without)	0.759			
Treatment of diabetes (with vs without)	0.601			
Systolic BP at baseline ($\geq$130 vs <130) (mmHg)	0.618			
Diastolic BP at base line ($\geq$69 vs <69) (mmHg)	0.761			
Macrovascular invasion (with vs without)	0.725			
Extrahepatic metastasis (with vs without)	0.151			
History of MTAs (with vs without)	0.685			
UPCR at baseline ($\geq$0.35 vs <0.35) (g/gCre)	0.022	3.326	0.882-12.540	0.076
Average systolic BP ($\geq$135 vs <135) (mmHg)	0.003	6.909	1.436-33.230	0.016

*Log-rank test, ** Cox proportional hazard regression.
HR, hazard ratio; CI, confidence interval; ECOG, eastern cooperative oncology group; ALBI, albumin-bilirubin; eGFR, estimated glomerular filtration rate; BP, blood pressure; MTA, molecular targeted agent; UPCR, urinary protein-to-creatinine ratio.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6